MBX Biosciences (MBX) Cash from Operations (2023 - 2026)

MBX Biosciences has disclosed Cash from Operations across 4 years of filings, most recently posting 20208000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 20208000.0, up 10.89% year-over-year; the trailing twelve-month figure through Mar 2026 was 77479000.0 (down 16.25% YoY), and the FY2025 annual result was 79949000.0, down 46.21% from the prior year.
• Cash from Operations came in at 20208000.0 for Q1 2026 at MBX Biosciences, down from 18301000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 10710000.0 in Q1 2024 to a low of 22678000.0 in Q1 2025.
• The 4-year median for Cash from Operations is 16735500.0 (2024), against an average of 16598400.0.
• Across the five-year window, Cash from Operations slumped 111.75% in 2025 and grew 10.89% in 2026, its largest moves.
• MBX Biosciences' Cash from Operations stood at 11146000.0 in 2023, then plunged by 43.88% to 16037000.0 in 2024, then retreated by 14.12% to 18301000.0 in 2025, then dropped by 10.42% to 20208000.0 in 2026.
• The last three Cash from Operations figures came in at 20208000.0 (Q1 2026), 18301000.0 (Q4 2025), and 21536000.0 (Q3 2025), per Business Quant data.